- Pharmaxis Home
- About Us
- Our Products
- Investors
- News
- Research & Development
- Contact Us
- Health Professionals
- Distributors
- Patients
Pharmaxis was founded more than ten years ago on an important Australian research discovery. Today, Pharmaxis is working to bring innovative medicines to millions of people worldwide, touching and improving their lives as it does so.
Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for under-treated respiratory diseases. Our therapeutic interests include lung diseases such as cystic fibrosis, bronchiectasis and asthma; as well as chronic obstructive pulmonary diseases such as chronic bronchitis and pulmonary fibrosis.
The company's first product, Aridol, is designed to identify twitchy or hyper-responsive airways and to assist in diagnosing and managing asthma. Aridol is approved for sale in Australia, major European countries and Korea. In May 2009 a New Drug Application (NDA) was accepted by the United States Food and Drug Administration for review.
The second product, Bronchitol is designed to restore normal lung hydration, improve lung function and to help relieve the mucus burden in the lungs of patients suffering from chronic respiratory conditions. Bronchitol has completed the first regulatory Phase 3 clinical trials in both cystic fibrosis and bronchiectasis.
Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in November 2003 (symbol PXS).
Headquartered in Sydney at its TGA-approved manufacturing facilities, Pharmaxis has grown to become one of Australia's largest life sciences companies, with offices in four continents.
Pharmaxis is committed to bringing therapeutic advances for respiratory diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that's built to last.
Click here to download a copy of the Pharmaxis Company Profile
Please select from the list below to view the Pharmaxis 2009 Statutory Annual Report which contains detailed disclosure on the following information: